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Abstract
Background: The purpose of this study was to evaluate the efficacy and safety of three nevirapine-based antiretroviral
treatments for adult antiretroviral-naı ¨ve Chinese patients with HIV-1 infection.
Methodology: This was a prospective, multicenter study. 198 antiretroviral-naı ¨ve HIV-1 positive subjects with CD4
lymphocyte counts between 100/ul and 350/ul and plasma HIV-1 RNA levels more than 500 copies/ml were randomized to
start three NVP-based antiretroviral treatments: group A, NVP+AZT+ddI; group B, NVP+3TC+d4T; group C, NVP+AZT+3TC.
Viral responses, immunologic responses, adverse events and drug resistence were monitored at baseline and the end of
week 4, 12, 24, 36, 52. Viralogical response and immunological response were also comparaed in different strata of baseline
CD4 T lymphocyte counts and plasma HIV-1 RNA concentrations. At baseline, the plasma HIV-1 RNA was 4.4460.68,
4.5260.71 and 4.4160.63 lg copies/ml in group A, B and C respectively (p=0.628). At the end of the study, the plasma viral
load reached 2.5461.11, 1.8960.46 and 1.9260.58 lg copies/ml in group A, B and C respectively (p,0.001). At week 52,
suppression of plasma HIV-1 RNA to less than 50 copies/ml was achieved in more patients in group B and C than in group A
(68.2%, 69% vs. 39.7%; p,0.001). In planned subgroup analyses, the decrease of viral response rate was seen in group A
when CD4 cell count .200/ul (subgroup H). But in subgroup L, viral response rate of three groups has no significant statistic
difference. There were no statistically significant differences among three groups in immunological response wthin any of
the CD4 or pVL strata. 3 out of 193 patients with available genotype at baseline showed primary drug resistant. Of 26
patients with virologic failure, 17 patients showed secondary drug resistant, 16 subjects in group A and 1 subject in group B.
Logistic regression analysis indicated that presence of hepatotoxicity was associated with HCV-Ab positive (OR=2.096,
95%CI: 1.106–3.973, P=0.023) and higher CD4 baseline (CD4 count .250/ul)(OR=2.096, 95%CI: 1.07–4.107, P=0.031).
Conclusion: Our findings strongly support the use of 3TC+d4T and 3TC+AZT as the nucleoside analogue combination in
NVP-based antiretroviral therapy. The regimen of AZT+ddI+NVP produced poor virological response especially in the
stratum of CD4 count more than 200/ul. More patients showed secondary drug resistant in this arm too. Patients with HCV-
Ab+ and CD4 count .250/ul appear to have significantly high risk of hepatoxicity.
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Introduction
Acquired immunodeficiency syndrome (AIDS) is a life-threating
disease caused by human immunodeficiency virus (HIV). The
advent of highly active antiretroviral therapy (HAART) has
resulted in profound suppression of HIV replication, substantial
increase of CD4+ T cells and partial reconstitution of the immune
system.[1] All of these result in significant declines in morbidity
and mortality from HIV/AIDS. In Western countries, twenty
individual antiretroviral drugs, four fixed dose two-drug combi-
nations, and two fixed dose three-drug combinations are available
and many prospective, randomized clinical trials were performed
to assess the efficacy and safety of HAART.[2] All these robust
evidences were utilized to constitute the guidelines for occidental
HIV/AIDS patients. In China, there are 650,000 people who are
living with HIV infection, including about 75,000 AIDS
patients.[3] Chinese government provide seven kinds of free-of-
charge antiretroviral drugs which include Zidovudine (AZT),
Stavudine (d4T), Lamivudine (3TC), Didanosine (ddI), Nevirapine
(NVP), Efavirenz (EFV) and Indinavir (IDV). They are all generic
drugs except for 3TC and EFV. About 16,000 AIDS patients have
been treated with free-of-charge antiretroviral therapy. [4] The
PLoS ONE | www.plosone.org 1 December 2008 | Volume 3 | Issue 12 | e3918most popular drug combinations in China were NVP-containing
regimens because of their convenience and tolerability. However
limited data was come from trials of Chinese patients and no
prospective randomized trial of different NVP-containing
HAART strategies in treatment-naı ¨ve HIV-1 infected subjects
was performed to give the evidences to verify their efficacy and
safety in Chinese patients. To address this question, we compared
three regimens containing the nonnucleoside reverse-transcriptase
inhibitor NVP with the combination of two nucleoside reverse-
transcriptase inhibitor AZT+ddI, 3TC+d4T or AZT+3TC with
respect to antiretroviral potency, immunologic reconstitution,
safety, tolerability, and the potential for drug resistence.
Methods
The protocol for this trial and supporting consort checklist are
available as supporting information; see Checklist S1 and Protocol
S1.
A. Patients
This study was approved by the ethics committee of Peking Union
Medical College Hospital. Enrollment began in January 2005.
Patient Information and Consent to Medical Treatment and sign a
written consent form. Consenting individuals 18 years or older were
recruited from thirteen research centers of China. They were found
to be HIV-seropositive by standard serum enzyme-linked immuno-
sorbentassay(ELISA)testsand alsobyWesternblotanalysis.Patients
were considered for inclusion in this study if they were antiretroviral
drug-naı ¨ve. The eligibility criteria for participants were CD4+ T-cell
count from 100 to 350 cells/mm3; plasma viral load over 500copies/
ml. Main exclusive criteria were pregnancy or breastfeeding,
anticipated nonadherence, AIDS-defining illness within 2 weeks of
entry, white blood cell count less than 2.06109/L, absolute
neutrophil count less than 1.06109/L, hemoglobin level less than
90g/l, platelet count less than 0.7561012/L, transaminase and
alkaline phosphatase level more than 3 times the upper limit of the
normal range, bilirubin level more than 2.5times the upper limit of
the normal range, serum creatinine level more than 1.5 times the
upper limit of the normal range.
Patients were randomly allocated to three treatment groups:
group A, AZT(300mg twice daily [bd])+ddI (200mg bd or 125mg
bd when less than 60kg)+NVP(200mg once daily for 2 weeks and
200mg bd thereafter); group B, 3TC(150mg bd)+d4T(30mg bd or
20mg bd when less than 60kg)+NVP; group C, AZT+3TC+NVP.
(AZT, ddI, d4T and NVP are generic which made in China.) For
farther analysis, patients were stratified by baseline CD4+T cell
count: Subgroup L was defined as the baseline CD4+T cell #200/
ul; subgroup H was defined as the baseline CD4+T cell .200/ul,
and baseline plasma viral load (pVL): subgroup A, the pVL
#10,000copies/ml; subgroup B, the pVL .10,000 and
#100,000copies/ml; subgroup C, the pVL.100,000copies/ml.
Patients were also stratified by baseline CD4+ T cell#250/ul or
CD4 + T cell.250/ul in the analysis of adverse effects.
B. Methods
a) The present study was divided into a screening period of 1–
4 weeks and a follow-up period of one year. At the end of the
screening period, the eligible patients were randomly
allocated to one of the three treatment groups. The
randomization was performed by drawing of envelopes.
The follow-up period then started, with five visits at 4, 12, 24,
36, 52 weeks. During all of the visits the clinical assessment
was recorded in the CRF and the subjects had samples taken
for laboratory assessment and further detection including T
cell subset, pVL and analysis of genotype resistance. The
adverse events were classified and graded according to
division of AIDS table for grading the severity of adult and
pediatric adverse events.[5]
b) Viral load:Plasma was separated from whole blood by
centrifugation within 4h of collection and was stored frozen
at 280uC until tested. The QUANTIPLEX HIV-1 RNA
assay, version 3.0 (bDNA 3.0 assay), was performed according
to the manufacturer’s instructions that were provided with the
assay kit. The limits of detection of the assay, indicated by the
manufacturer, was 50,500,000 HIV-1 RNA copies/ml.
c) Immunofluorescent surface staining and flow cytometric
analysis:Peripheral blood mononuclear cells were obtained
by separation from the centrifugation gradient. Subpopula-
tions of CD3+, CD4+, and CD8+ cells were determined by
three-color flow cytometry (Beckman-Coulter, USA) at
baseline and at the end of week 4, 12, 24, 36, 52. The
following groups of monoclonal antibodies were used: PEcy5-
CD4/PE-CD8/FITC -CD3 (CD4+/CD8+T cell counts). All
monoclonal antibodies were purchased from Beckman-
Coulter and Immunotech, USA.
d) Blood routines, liver functions, sero-amylase, HCV-Ab, and
serum lipids were administered by the clinical laboratory
department of each research centers.
e) Genotype resistance: Viral RNA was extracted from the
isolated viruses using a QIAamp Viral RNA Mini Kit
(Qiagen Inc., Chatsworth, CA) according to the manufac-
turer’s protocol, and stored at 270uC until use. Reverse
transcript reaction was run to synthesis of cDNA. The 1100-
bp pol gene fragment encompassing the complete protease
gene and the first 220 codons of the RT gene of HIV-1 RNA
were amplified by nested PCR strategy and purified using a
QIAquick Gel Extraction Kit (Qiagen Inc.). The product was
sequenced and the results were compared to the consensus B
reference sequence using HIVdb software (Stanford HIV
Drug Resistance Database, http://hivdb.stanford.edu) to
detect drug-resistance mutations. The protocol of nest PCR
and DNA sequencing were described elsewhere.[6] Some of
HIV-1 analysis was performed with the ViroSeq system
according to the manufacturer’s instructions as the quality
control and remedy for in-house testing.
f) Sample size and statistical analysis:
i. Sample size was calculated according to the both of the
following criteria: CD4+ cells were detected at least 30
percent increasing than the baseline value; and the average
efficient rates in CD4+ increasing of three treatment groups at
least reached to 70 percent. In order to detect such a
difference (with 80% power and 95% confidence) we need
about 60 patients in each treatment group. Allowing for 20%
loss to follow up, a total sample of 220 was required.
ii. All statistical analysis was performed using the SPSS 11.5
statistical package. In present study, we performed two
separate and complementary analyses of these data: the
analysis according to the actual treatment and the intention-
to-treat analysis. For the analysis according to actual
treatment, we included only patients for whom outcomes
were measured at specified time points. The intention-to-treat
analysis involved patients who underwent randomization,
received at least one dose of study medication, and had at least
one plasma HIV-1 RNA measurement after treatment began.
Missing values were imputed for the analysis with the use of a
Generic NVP-Based ART Study
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outcome variable is considered, we use analysis of covariance
to control for baseline variables. The change between the
baseline value and the follow-up value of a particular outcome
is evaluated by Kruskal-Wallis test or Mann-Whitney U test.
Using a chi-square test, we compared the rates of response
among the treatment groups in terms of the percentage of
patients with suppression of plasma HIV-1 RNA levels to less
than 400 copies per milliliter as well as the percentage for
whom it was less than 50 copies per milliliter. Multivariate
logistic regression analyses were used to identify factors
associated with the presence of certain outcome. For all tests,
P,0.05 was considered to be statistically significant.
Results
A. Baseline characteristics
Of the 362 subjects screened, 198 HIV-positive antiretroviral-
naive patients were recruited into this study. Demographic
characteristics of the groups are summarized in Table 1. There
were no statistically significant differences among the there
treatment groups at baseline except for age, which was
significantly older in the group B. The disposition of patients in
the study shows in Figure 1.
B. Plasma viral load response
In an intent-to-treat (ITT) analysis, the changes of plasma viral
load during 52-week HAART in group A, B and C, are shown in
Figure 2. After 4 weeks of HAART, plasma viral loads dropped by
a mean of 2.1460.57 lg copies/ml. At the end of the study, plasma
viral loads dropped by a mean of 1.8861.09 lg copies/ml in group
A, 2.6960.69 lg copies/ml in group B, 2.3760.95 lg copies/ml in
group C. The magnitude of the decrease in plasma VL of group B
and C were significantly more than that of group A (P,0.001).
110 patients (58.8%) achieved a plasma VL of ,50 copies/ml,
155 patients (82.9%) achieved a plasma VL of ,400copies/ml.
The percentage of patients who achieved a plasma VL of ,50
copies/ml was 39.7% in group A, 68.2% in group B and 69% in
group C (P,0.001). The percentage of patients who achieved a
plasma VL of ,400 copies/ml was 63.5% in group A, 92.4% in
group B and 93.1% in group C (P,0.001).
The viral response rate was analyzed when the subjects stratified
by baseline CD4+T cell count. The baseline pVLs were
4.6760.63 lg copies/ml in subgroup L and 4.2960.66 lg
copies/ml in subgroup H (P,0.001). At the end of 52 weeks,
the pVL reached 2.0760.80 lg copies/ml in subgroup L and
2.0960.77 lg copies/ml in subgroup H (P=0.744). The viral
response rate of patients who divided into three therapy groups
and stratified by baseline CD4+T cell count are showed in
Figure 3. The viral response rate was higher in group B and C
when the baseline CD4+T cell count was more than 200/ul
(subgroup H). But this trend was not significant in subgroup L.
When the subjects were stratified by baseline viral load, the viral
response rates were 68.9%, 56.1%, 54.5% in subgroup a, b and c
respectively (P=0.285).
C. Immunological response
The increase in CD4+T cell count was divided into two phases:
a rapid increase in the first 12 weeks constituted the first phase and
a slow increase after week 12 constituted the second phase. The
increased magnitudes of CD4+T cell count were 72/ul at week 4
and 105/ul at week 12. At the end of the study, the increased
magnitudes of CD4+T cell count reached 149/ul. There was no
significant difference among the mean CD4+T cell count of three
groups at weeks 4, 12, 24, 36, 52. (Figure 4)
When the subjects stratified by baseline CD4+T cell count, the
CD4+T cell count reached 2896128/ul at subgroup L and
4326144/ul at subgroup H (P=0.581) at week 52. The increase
trends of CD4+T cell count in two subgroups were parallel to each
other. In each subgroup, there is no statistic difference of mean
CD4+T cell count and the increased magnitute of CD4+T cell
count in three treatment groups.
When the subjects stratified by baseline pVL, the baseline
CD4+T cell counts were 250668/ul in subgroup A, 216674/ul in
subgroup B, 195673/ul in subgroup C (P,0.001). At the end of
this study, CD4+T cell count reached 3666139/ul, 3686158/ul,
3386163/ul in subgroupA,B, C (P=0.172).
There is no statistical difference of CD8+T cell count and CD4/
CD8 ratio of three therapy groups at the baseline and at weeks 4,
12, 24, 36, 52.
D. Clinical outcomes and adverse events
After 52 weeks of HAART, totally 14 patients (7.1%) lost to
follow-up. In remain 184 patients, common complaints, such as
fatigue, malaise and weight loss, were released at the end of this
study. No one developed new AIDS-defining illness and died.
285 cases of adverse events occurred in 198 subjects. The details
can be seen in Table 2. More than 85% adverse events mainly
Table 1. Demographic characteristics of patients of each group
Intention-to-treat Actual-treat
AZT+ddI+NVP
Group A (n=65)
3TC+d4T+NVP
Group B (n=69)
3TC+AZT+NVP
Group C (n=64)
AZT+ddI+NVP
Group A (n=46)
3TC+d4T+NVP
Group B (n=53)
3TC+AZT+NVP
Group C (n=44)
Male (n(%)) 34 (52.3%) 31 (44.9%) 31 (48.4%) 24(52.2%) 23(43.4%) 24(54.5%)
Female (n(%)) 31 (47.7%) 38 (55.1%) 33 (51.6%) 22(47.8%) 30(56.6%) 20(45.5%)
Age(years) Mean6SD 35.868.7 40.1610.8 37.369.5 36.5(9.4%) 41.3(10.2%) 37.1(8.9%)
Prior AIDS (n(%)) 2(3.1%) 2(2.9%) 4(6.3%) 0 2(3.8%) 2(4.5%)
CD4+ count(cells/ul) Mean6SD 221.8673.4 218.5684.0 224.0673.5 234.2671.0 207.8675.0 219.6670.8
Plasma HIV-RNA(log10copies/ml)
Mean6SD
4.4460.68 4.5260.71 4.4160.63 4.3760.71 4.5860.62 4.4360.63
HCV-Ab positive (n(%)) 21(32.3%) 21(30.4%) 16(25%) 15(34.1%) 14(32.6%) 9(23.1%)
HBsAg positive (n(%)) 6(9.2%) 4(5.8%) 2(3.1%) 2(4.5%) 4(9.1%) 1(2.6%)
doi:10.1371/journal.pone.0003918.t001
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The total AEs of each group has no statistic significant difference.
37 patients changed the corresponding drug because the adverse
events were intolerable and could not be controlled by symptomatic
treatment. (Figure 1) Bone marrow suppression mainly occurred in
group C, in which the treatment contains AZT and 3TC.
In patients in all three groups, the most common treatment-related
adverse events were hepatotoxicity. It occupied 47.1% severe adverse
events (grade 3–4). The ratio of severe hepatotoxicity was 12/
64(18.8%), 19/69(27.5%), 10/65(15.4%) respectively in treatment
group A, B, C. Multivariate logistic regression analyses were used to
identify factors associated with the presence of hepatotoxicity (grade
2–4). Patients have higher CD4 baseline (CD4 count .250/
ul)(OR=2.096,95%CI:1.07–4.107,P=0.031)andHCV-Abpositive
(OR=2.096,95%CI:1.106–3.973,P=0.023)weremorelikelytohave
hepatotoxicity after controlling for treatment group and the gender. If
the subjects divided by the gender, logistic regression analyses showed
that higher CD4 baseline (CD4 count .250/ul) increased the odds of
developing hepatotoxocity in women (OR=2.784, 95%CI: 1.128–
6.874, P=0.026) but not in men(P=0.511). The bone morrow
suppression occupied 29.9% severe adverse events (grade 3–4).
E. Genotypic Analysis
Genotypic testing was carried out on baseline specimens and on
specimens with pVL more than 1000copies/ml after 12 weeks. At
baseline, among the 193 patients for whom HIV-1 RNA could be
amplified, 3 subjects had isolates showing resistance mutations.
At virologic failure after 12-week therapy, of 26 patients without
preexisting resistance, 17 patients had genotypic results available.
Of the 17 with genotypic information available, 16 patients were
in group A, and the other one was in group B. The mutations
mostly occurred at 24-week therapy. Mutations related to NNRTI
(K103N/R, Y181Y/C, G190A, V106A, V179T/D, Y188L/C,
K101E, F227L) were detected in 17 patients. Mutations related to
NRTI (M41L, A62V, K65R, D67N/S, T69N/S, K70R, L74V,
V75M, V118I, M184V, L210W, T215Y, 151 Complex) were
detected in 8 out of 17 patients.
F. HCV coinfection
175 patients had HCV-Ab test at baseline. 58 subjects (29.3%)
were HCV-Ab positive. The baseline HIV pVL of HCV(+)
subjects and HCV(2) subjects were 4.4360.72 copies/ml,
4.4760.64 copies/ml (p=0.75). The baseline CD4+T cell count
of HCV(+) subjects and HCV(2) subjects were 231.1675.6/ul,
218.0675.3/ul (p=0.281). At the end of this study, 57.4%
HCV(+) patients and 57.9% HCV(2) patients achieved a pVL of
less than 50copies/ml (p=0.952). The increased magnitute of
CD4+T cell count was 169.36123/ul in HCV(+), 131.76121/ul
in HCV(2) (p=0.162).
As we metioned before, logistic regression analysis indicated
that presence of hepatotoxicity was independently associated with
HCV-Ab positive (OR=2.096, 95%CI: 1.106–3.973, P=0.023).
Discussion
NVP-based antiretroviral treatments are most accessible
regimens in China. This was a prospective, multicentre study to
evaluate three NVP-based regimens in terms of antiviral efficacy
and tolerability in Chinese HIV-1 infected patients.
Figure 1. Disposition of patients (AZT, zidovudine; ddI, didanosine; NVP, nevirapine; 3TC, lamivudine; d4T, stavudine)
doi:10.1371/journal.pone.0003918.g001
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containing antiretroviral therapy has been scarce. The dissimilar
criteriausedofinclusionandexclusioninthestudiesmakesitdifficult
to compare the efficacy of the regimens with different nucleoside
backbones described in the different trial. In this study, we found
significant difference over 52 weeks among three NVP-based
regimens in the initial treatment of HIV-1 infection with regard to
virologic response and resistance mutation. The regimen of
AZT+ddI+NVP produced poor virological response especially in
the stratumofCD4 count morethan 200/ul.In theINCAS trail, the
Figure 2. The plasma VL of three treatment groups. According to an analysis based on the intention-to-treat analysis (a) and actual treat
analysis (b).P value is calculated by comparing the plasma VL of three groups.
doi:10.1371/journal.pone.0003918.g002
Generic NVP-Based ART Study
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16, with 68% of patients demonstrating a pVL,20 copies/ml, with
51% maintaining this level of suppression at week 52.[7] One of the
inclusion criteria of the INCAS trial was CD4+T cell count between
200–600/ul. The discrepancy of virological response probably
attribute to different ethnic group and CD4+Tc e l ls t r a t u m .F e w
studiestook theAZT+ddI+NVP regimen asanindependent arm.So
the result of this trial must be confirmed in other studies. Contrarily,
the effect of treatment arm on the increase in CD4 count over time
did not reach statistical significance.
In this study, two of the NVP-containing regimens:
NVP+d4T+3TC, NVP+AZT+3TC, are effective in ART-naı ¨ve
patients, producing a durable virological and immunological
response. There are no significant differences over 52 week
between these two regimens with regard to virological response,
immunological response, adverse events or resistance mutations at
virologic failure. In a comparison with an Australian trial of the
same NRTIs with NVP, the 3TC+d4T and 3TC+AZT arm of the
current study had similar proportion of patients at the end of the
study with plasma HIV RNA ,50copies/ml. [8] And the finding
of comparable virological efficacy between these two regimens in
suppression to a pVL,400 copies/ml is compatible with the
results of a systematic review of triple combination therapies in
antiretroviral therapy-naı ¨ve patients.[9] In this review, for patients
using two NRTI and one NNRTI the overall percentage of
patients achieving a pVL,400copies/ml after 48 weeks were 73%
and the overall percentage of patients achieving a pVL,50copies/
ml after 48 weeks were 64%. Our findings strongly support the use
of 3TC+d4T and 3TC+AZT as the nucleoside analogue
combination.
There were no statistically significant differences of virological
response in any pVL or CD4 count strata. After 4-week therapy,
there were no statistically significant differences of pVLs in any
strata at all. And this trend lasted until the end of the study. Lower
CD4 cell counts and higher viral loads at baseline were not
associated with poorer virological outcome of HAART. A report
from Andrew Phillips,[9] which was based on a large Europe
cohort of patients starting HAART, found results broadly
consistent with our own. On the other hand, in terms of
immunological response, higher viral loads at baseline indicated
greater increase in CD4 cell count. This is in line with one of the
findings of the ACTG study.[10] This may be because of
eliminating the high stress of viral load result in significant CD4
cell count recovery. But at the end of this study, the advantage of
great increase in CD4 cell count disappeared gradually. In western
country, large cohort study demonstrated disease progression to
death and AIDS or death was clustered among patients starting
antiretroviral therapy with high pVL.[11] It is needed to evaluate
not only immunological response but also survival rate in a long-
term assessment.
Figure 3. Percentage of patients with plasma VL of ,50 copies/ml and ,400 copies/ul at week 52. According to an analysis based on the
intention-to-treat analysis (a, c) and actual tren\atment analysis (b, d). P values are calculated by pair wise comparing the viral response rate of two
groups at week 52.
doi:10.1371/journal.pone.0003918.g003
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PLoS ONE | www.plosone.org 6 December 2008 | Volume 3 | Issue 12 | e3918Figure 4. The increase of mean CD4+T cell count in three therapy group during HAART. According to an analysis based on the intention-
to-treat analysis (a) and actual treat analysis (b). P value is calculated by comparing the CD4+ T cell count of three groups.
doi:10.1371/journal.pone.0003918.g004
Generic NVP-Based ART Study
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with HIV-1 in North America and Europe. [12–14] But in this
study, primary resistance rate is much lower than reports from
western country. This discrepancy occurs because antiretroviral
therapeutics was available in china much later than weastern
country and many of Chinese AIDS patients have been treated
with free-of-charge HAART since 2003. One of the main results of
this study was that there was a trend toward higher drug resistance
rate in AZT+ddI+NVP group. This result explained, at least in
part, the higher rate of virologic failure in this group. The higher
rate of gastrointestinal disorders and food restrictions of ddI in this
therapy group may affect treatment comp1iance. This may be the
intrinsic reason of virological failure and drug resistance.[15]
The safetyprofilesofthe three therapeuticarmswerealsoassessed
in present study. Hepatotoxicity was the major adverse events of
NVP-based therapy. Stern JO and his colleagues reported the
increased risk of severe hepatotoxicity in women with CD4 count
.250/ul and men with CD4 count .400/ul.[16] The result of this
study is in line with the findings of Stern JO. The odds of
hepatotoxicity increased significantly when baseline CD4 count is
over 250/ul in all subjects and subgroup of women. The enrolling
criterion of baseline CD4 count limits the analysis of odds of
hepatotoxicityinmen.Thisresultsupportsthehypothesisthatoneof
the mechanisms of hepatotoxicity is the hypersensitivity reac-
tion.[17] To our knowledge this is the first study that reports the
association between the incidenceof hepatotoxicityand the stratified
baseline CD4 count in Chinese.Another important mechanism of
hepatotoxicity is chronic viral hepatitis coinfection. We also found
the association between the occurrence of hepatotoxicity and HCV
antibody positive. This resultis inline with the reportofSulkowski et
al.[18] The overall incidence of hepatotoxicity is 20.7%, a little
higher than the reports of Sulkowski et al[18] and 2NN study.[19]
This differences may be explained by demographics.
The incidence of hyperlipidemia in treatment group A and C is
accordant with the result of 2NN.[19] A higher rate of
hyperlipidemia was found in treatment group B in the present
study. This is probably related to the presence of d4T in the
backbone nucleoside combination, a NRTI that is more likely to
cause hyperlipidemia than AZT and 3TC.[20][21] But the
lipodystrophy was not occurred in this study because of the
relative short period of study.
All of the three therapeutic arms contain at lest one of AZT and
3TC. As the papers reported [22] [23], the hematologic toxic
effects developed in three groups almost evenly. This adverse event
occupied 29.9% severe adverse events of this study and mostly
occurred in the early three months of the treatment.
The adverse events such as rash, gastrointestinal disorders,
peripheralneuropathy are always mild and can be controlled by
symptomatic therapy. But it is important to well handle these
adverse events because it may affect the adherence of HAART.
In conclusion, as virological response and incidence of viral
resistance has been concerned, 3TC+d4T and 3TC+AZT as the
nucleoside analogue combination of NVP-based HAART is
recommended. The diversity of immunological response of three
NVP-based arm do not reach the statistic significant. We
confirmed that incidence of hepatotoxicity is significantly higher
in subgroup of CD4 count .250/ul and subjects with HCV-Ab
positive in Chinese.
Supporting Information
Checklist S1 CONSORT Checklist
Found at: doi:10.1371/journal.pone.0003918.s001 (0.05 MB
PDF)
Protocol S1 Trial Protocol
Found at: doi:10.1371/journal.pone.0003918.s002 (0.07 MB
PDF)
Acknowledgments
The following clinical Insititutions or Hospitals participated this study:
Beijing Youan Hospital; Beijing1 Ditan Hospital; The First Affiliated
Hospital, Henan Medical University; Xian Tangdu Hospital; The 2
th
Affiliated Hospital, Xiangya Medical University; The Shanghai Public
Health center; The Shenzhen CDC, The 8
th Hospital of Guangzhou, The
HIV/AIDS Care Center of Yunnan; Zhejiang Medical University.
Author Contributions
Conceived and designed the experiments: TL YH JX. Performed the
experiments: TL YD JK YH ZQ JX LZ YL. Analyzed the data: TL YD JK
JJ. Contributed reagents/materials/analysis tools: TL JJ. Wrote the paper:
TL YD.
Table 2. The adverse events happened in this study in each treatment group (cases)
Adverse events Treatment Groups
Possible corresponding
drugs
Group A Group B Group C
AZT+ddI+NVP 3TC+d4T+NVP AZT+3TC+NVP
grade 2 grade 3 grade 4 grade 2 grade 3 grade 4 grade 2 grade 3 grade 4
Hepatotoxicity 13 8 4 14 11 8 9 6 4 NVP
Hyperlipidemia 15 2 0 17 8 0 11 2 0 d4T/AZT/3TC
N e u t r o p e n i a 530721864 AZT/3TC
A n e m i a 002120502 AZT/3TC
Thrombocytopenia 4 2 0 810500 AZT/3TC
R a s h 7001 1 00800 N V P
Gastrointestinal disorders 18 5 0 10 0 0 18 3 0 AZT/ddI
Peripheralneuropathy 2 0 0 110100 d d I / d 4 T
Total 64 20 6 69 25 9 65 17 10 -
doi:10.1371/journal.pone.0003918.t002
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